PHARMA MAR
ActivePHARMA MAR has been active since 2015 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €223k and a net result of €8k. Equity is growing by ~11.2% per year across the filed fiscal years. Its solvency ranks better than 46% of 64 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 1.3% (low).
Checked score
Score 2025
87
/ 100
Excellent= vs 2024
The score combines four axes. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability18▲+4
Solvency89▲+9
Growth78=
Stability100
Bankruptcy probability, 12 months
1.3%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €19k at 30 days acceptable
Liquidity ample (current ratio 1.93 against 1.78 in 2024), but 54.6% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
45.4%
Return on assets
1.7%
Age of the figures
8 mo
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Sector 21
higher
← fewer bankruptcies
more bankruptcies →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 20-03-2026, 133 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
133 d early
2024
55 d early
2023
47 d early
2022
25 d early
2021
11 d early
2020
2 d late
2019
24 d late
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
15-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, full schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€8k▲ 39.8%
2024 · €6k
2018: €-13k
2019: €-15k
2020: €34k
2021: €27k
2022: €42k
2023: €-789
2024: €6k
2018 → 2025
Working capital
€234k▲ 3.5%
2024 · €226k
2018: €132k
2019: €104k
2020: €148k
2021: €181k
2022: €224k
2023: €218k
2024: €226k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€168k-€210k▲ 25.0%€209k▼ 0.4%€215k▲ 2.8%€223k▲ 3.8%
Operating result€49k-€56k▲ 14.2%€22k▼ 61.2%€20k▼ 6.4%€20k▼ 0.1%
Net result€27k-€42k▲ 56.0%€-789€6k€8k▲ 39.8%
Result per fiscal year
Operating resultNet result
The operating result has fallen three years in a row; 2025 is 0% below 2024 and is the lowest year so far.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €493k
Fixed assets
€6k▼ 31.9%
Current assets
€486k▼ 6.1%
Equity and liabilities €493k
Equity
€223k▲ 3.8%
Debt
€269k▼ 13.6%
The debt ratio falls from 59.2% to 54.6%: equity grows while debt is paid down.
Key figures and ratios
EBITDA
€23k▲
2024 · €23k
Cash flow
€11k▲
2024 · €8k
Solvency
45.4%▲
2024 · 40.8%
Current ratio
1.93▲
2024 · 1.78
Quick ratio
1.93▲
2024 · 1.78
Debt / equity
1.21▼
2024 · 1.45
ROE
3.7%▲
2024 · 2.7%
ROA
1.7%▲
2024 · 1.1%
Interest coverage
5.68▲
2024 · 4.77
Debt
€269k▼
2024 · €312k
Debt ≤ 1 year
€252k▼
2024 · €291k
Income taxes
€8k▼
2024 · €10k
Staff costs
€533k▼
2024 · €605k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€527k€493k▼
Fixed assets21/28€9k€6k▼
Tangible fixed assets22/27€5k€2k▼
Furniture and vehicles24€5k€2k▼
Financial fixed assets28€4k€4k=
Current assets29/58€518k€486k▼
Amounts receivable after more than one year29€800€800=
Other amounts receivable291€800€800=
Amounts receivable within one year40/41€312k€374k▲
Trade receivables40€275k€341k▲
Other amounts receivable41€37k€33k▼
Cash at bank and in hand54/58€197k€103k▼
Deferred charges and accrued income490/1€8k€8k▲
Equity and liabilities
Total equity and liabilities10/49€527k€493k▼
Equity10/15€215k€223k▲
Contributions10/11€150k€150k=
Profit (loss) carried forward14€65k€73k▲
Amounts payable17/49€312k€269k▼
Amounts payable within one year42/48€291k€252k▼
Trade debts44€15k€37k▲
Suppliers440/4€15k€37k▲
Taxes, remuneration and social security45€212k€153k▼
Taxes450/3€19k€17k▼
Remuneration and social security454/9€193k€136k▼
Other amounts payable47/48€65k€62k▼
Accrued charges and deferred income492/3€20k€17k▼
Income statement
Code20242025
Remuneration, social security and pensions62€605k€533k▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€2k€3k▲
Other operating charges640/8€67k€98k▲
Gross operating margin9900€695k€654k▼
Operating profit (loss)9901€20k€20k▼
Financial income75/76B€0€0▼
Recurring financial income75€0€0▼
Financial charges65/66B€5k€4k▼
Recurring financial charges65€5k€4k▼
Profit (loss) for the period before taxes9903€16k€16k▲
Income taxes67/77€10k€8k▼
Profit (loss) for the period9904€6k€8k▲
Profit (loss) for the period to be appropriated9905€6k€8k▲
Appropriation of the result
Profit (loss) to be appropriated9906€65k€73k▲
Profit (loss) brought forward from the previous period14P€59k€65k▲
Social balance
Average headcount (FTE)90874.33.9▼
The notes to these accounts (8 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
20-03
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
2025
06-06
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
31-12
Financial
Back to profitnet €6k
Net result €6k after one loss-making year.
14-06
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
06-07
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
31-12
Financial
Highest result since 2018net €42k ▲56%
Operating result €56k, net result €42k, both a record.
31-12
Financial
Equity above €200kEq €210k ▲25%
3 profitable years in a row build equity to €210k.
20-07
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
2021
31-12
Financial
Equity above €150kEq €168k ▲19.1%
2 profitable years in a row build equity to €168k.
02-08
NBB filing
Annual accounts filed
fiscal year 2020 · full schema · 2 days late
2020
31-12
Financial
Back to profitnet €34k
Net result €34k after 2 loss-making years.
24-08
NBB filing
Annual accounts filed
fiscal year 2019 · full schema · 24 days late
2019
31-12
Financial
Weakest financial yearnet €-15k
Net result drops to €-15k, the lowest in the series; recovery starts the following year.
11-06
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
2018
18-06
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2017
21-06
NBB filing
Annual accounts filed
fiscal year 2016 · full schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
7 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Brussel · 2 establishment units since 2015
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Drukpersstraat 41000 BrusselGround area
261 m²
Building footprint
99 m²
Volume, LiDAR
2,129 m³
2 parcels, Brussels, Flanders · tallest building 23.6 m, ±8 floors. Linked by address, not a title deed.
2 establishment units
Drukpersstraat 4, 1000 Brussel
since 20152.244.408.665
Leonardo da Vincilaan 19, 1831 Machelen (Brab.)
since 20152.276.669.875
2 parcels
Flanders
1
(50%)
Brussels
1
(50%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 23015B0320/00D000indicative | Flanders | 161 m² | - | - |
| 21803C0244/00A002 | Brussels | 100 m² | 1 · 99 m² | 23.6 m · 8 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 1
1 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
TAKEAIR
BE 0658.744.222
Oudenaarde · Eq €226k
MEDIPHARM WORLDWIDE GROUP
BE 1017.902.558
Tienen · Eq €218k
MAKE IT WORK CONSULTING
BE 0784.837.589
Villers-la-Ville · Eq €210k
Plant Bio Technologies
BE 0537.556.083
Gent · Eq €240k
EQUIBOR
BE 0711.998.905
Manage · Eq €249k
Of 149 companies in sector 21100 we hold annual accounts for 108. 70 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded05-08-2015
Fiscal year end31-12
Activities, NACEBEL
21100Manufacture of basic pharmaceutical products and pharmaceutical preparations
21209Manufacture of basic pharmaceutical products and pharmaceutical preparations
46460Wholesale of pharmaceutical and medical goods
73110Advertising agencies
Sources
Crossroads Bank for EnterprisesNational Bank · 11 filingsAddress and cadastre registers
Data from official sources, last processed on 15-09-2026. Scores and ratios are computed by Checked and are not a credit decision.